What should be a 'golden era' in the development of vaccines is being threatened by a drive to cut costs, a report by a leading academic says.

Professor Louis Galambos, of John Hopkins University, said two thirds of world research and development is being conducted by European companies – but continuing pressure on prices could have a negative impact on investment.

For more details, visit www.euro.who.int